- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01524029
Digital Breast Tomosynthesis Versus Digital Mammography: A National Multicenter Trial
Digital Breast Tomosynthesis vs. Digital Mammography: A National Multicenter Trial
The goal of this study is to determine the value of the new mammography technique called Digital Breast Tomosynthesis (DBT) compared to the current standard technique Digital Mammography for the early detection of Breast Cancer.
DBT is able to compute a three-dimensional image of a breast from several low-dose mammographies taken from different angles while the device is moving around the breast in a circular motion. This should overcome a significant limitation of Digital Mammography arising from the masking of breast cancer in a mammography image caused by overlying normal breast tissue.
This is a study conducted in several Austrian Breast Imaging Centers.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
This prospective national multicenter multivendor trial aims at determining the impact of the novel technique Digital Breast Tomosynthesis (DBT) in the assessment and screening for breast cancer. Mammography is the primary imaging modality for the early detection of clinically occult breast cancer.
Despite advances in mammographic technique, mammography is still limited with regard to both sensitivity and specificity. In the majority of cases these limitations arise from the masking of subtle breast cancer lesions by overlapping breast tissue.
DBT is a novel technique that tries to overcome these limitations by performing a 3D-reconstruction of breast tissue from multiple low-dose digital mammographic images acquired in several planes in a 15 to 50 degree angle.
Early studies indicate an advantage of DBT compared to the standard Full Field Digital Mammography (FFDM) in terms of an improvement of specificity without cutback in sensitivity.
Controversy continues over the use of DBT in combination with FFDM or as a standalone screening method without concomitant 2D imaging. Unfortunately, the peer-reviewed publications evaluating DBT are limited and consist of single institution studies with a small number of participants.
The purpose of this study is to evaluate the novel technique of DBT compared to routine FFDM in a clinical large sample study (600 participants) to provide the path to implementation of this new technique into clinical and screening routine.
Studientyp
Einschreibung (Voraussichtlich)
Kontakte und Standorte
Studienorte
-
-
-
Vienna, Österreich, A-1090
- Rekrutierung
- Medical University of Vienna
-
Kontakt:
- Thomas Moritz, MD
- Telefonnummer: 4818 +43140400
- E-Mail: thomas.moritz@meduniwien.ac.at
-
Vienna, Österreich, A-1100
- Rekrutierung
- Kaiser Franz Josef Spital
-
Kontakt:
- Gabrielle Kienzer, MD
- Telefonnummer: 3608 +43160191
- E-Mail: Gabrielle.kienzer@wienkav.at
-
Vienna, Österreich, A-1140
- Rekrutierung
- Hanusch Krankenhaus
-
Kontakt:
- Reinhard Bernt, MD
- Telefonnummer: 86630 +43191021
- E-Mail: reinhard.bernt@wgkk.at
-
-
Styria
-
Graz, Styria, Österreich, A-8036
- Rekrutierung
- Medical University of Graz
-
Kontakt:
- Sabine Oswald, MD
- Telefonnummer: 13850 +43 316385
- E-Mail: sabine.oswald@klinikum-graz.at
-
-
Upper Austria
-
Wels, Upper Austria, Österreich, A-4600
- Rekrutierung
- Klinikum Wels-Grieskirchen
-
Kontakt:
- Stefan Meindl, MD
- Telefonnummer: 2413 +437242415
- E-Mail: stefan.meindl@klinikum-wegr.at
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
The study population consists of two groups:
One screening group consisting of asymptomatic women (Age 40+) referred for a screening mammography examination.
The second group consists of women aged 25+ referred for further examination of a breast lesion.
Beschreibung
Inclusion Criteria:
- Age > 25 years (40 years or older for Screening Cohort)
- No history of breast cancer
- Written informed consent
- Asymptomatic women in follow up for early detection of breast cancer or
- Patients with a recent positive mammography (BI-RADS 3-5)
Exclusion Criteria:
- Pregnant and breast feeding women
- Unable to tolerate breast compression
- Breast implants
- Unable to understand or execute written informed consent
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
---|
Breast Cancer Screening Patients
Group 1 consists of Women referred to Breast Cancer Screening examinations at a participating Austrian Breast Imaging Site
|
Diagnostic Patients
Patients referred to a participating Breast Imaging Center for a clinically or radiologically detected breast lesion
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Specificity of Digital Breast Tomosynthesis in the characterization of Breast lesions
Zeitfenster: One year
|
One year
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Sensitivity of Digital Breast Tomosynthesis in the detection of malignant breast lesions
Zeitfenster: One year
|
One year
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Thomas Moritz, MD, Medical University of Vienna
- Studienleiter: Thomas Helbich, MD Prof. MBA MSc, Medical University of Vienna
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- TomoTrial001
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Neoplasien der Brust
-
Novartis PharmaceuticalsAbgeschlossenMetastasierter Brustkrebs (MBC) | Locally Advance Breast Cancer (LABC)Vereinigtes Königreich, Spanien
-
BioNTech SESeventh Framework ProgrammeAbgeschlossenBrustkrebs (Triple Negative Breast Cancer (TNBC))Schweden, Deutschland
-
Filipa Lynce, MDAstraZeneca; Daiichi Sankyo, Inc.RekrutierungBrustkrebs | HER2-positiver Brustkrebs | Invasiver Brustkrebs | Entzündlicher Brustkrebs Stadium III | HER2 Low Breast AdenokarzinomVereinigte Staaten
-
John MascarenhasNational Cancer Institute (NCI); National Institutes of Health (NIH); Celgene... und andere MitarbeiterAbgeschlossenIDH2-Mutation | Accelerated/Blast-phase Myeloproliferative Neoplasm | Myelofibrose in der chronischen PhaseVereinigte Staaten, Kanada